<DOC>
	<DOCNO>NCT00968890</DOCNO>
	<brief_summary>The purpose present study assess immunogenicity , safety reactogenicity two-dose schedule vaccine GSK2340272A co-administered GSK Biologicals ' Fluarix™ vaccine either time first second vaccination elderly subject age 61 year old .</brief_summary>
	<brief_title>Immunogenicity Safety Vaccine GSK2340272A ( H1N1 ) GSK Biologicals Fluarix™ Vaccine When Co-administered Elderly</brief_title>
	<detailed_description>The study conduct open manner regard administration vaccine GSK2340272A . The study observer-blind regard administration Fluarix™ placebo vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject 61 year age old time first vaccination Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . Satisfactory baseline medical assessment history physical examination . Access consistent mean telephone contact . Previous administration 2009 Southern Hemisphere 20092010 Northern Hemisphere seasonal influenza vaccine . Previous administration pandemic influenza vaccine . Administration vaccine within 30 day first vaccination . Planned administration vaccine foreseen study protocol one month ( minimum 30 day ) second vaccination vaccine GSK2340272A . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine plan use study period . Potential subject followup ( i.e. , treatment ) phase prior investigational study may enrol investigator 's judgment effect safety , reactogenicity , immunogenicity endpoint study , violate protocol requirement prior trial . Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence oral temperature &gt; = 37.5°C , acute symptom great `` mild '' severity schedule date first vaccination . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Chronic administration immunosuppressant immune modify drug within six month prior first vaccination . Receipt immunoglobulins and/or blood product within 3 month precede first vaccination plan administration product entire study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome . Serious chronic disease determine medical history physical examination . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Any known suspected allergy constituent influenza vaccine . History chronic alcohol consumption and/or drug abuse . Clinically virologically confirm influenza infection within 6 month precede study start . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GSK Bio 's influenza vaccine GSK2340272A</keyword>
	<keyword>Influenza infection</keyword>
</DOC>